RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Clinical trials for RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR trials appear
Sign up with your email to follow new studies for RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug ivosidenib tested in kids with rare, returning cancers
Disease control OngoingThis phase 2 trial tested the drug ivosidenib in children and young adults (ages 1 to 21) with solid tumors, lymphomas, or histiocytic disorders that have an IDH1 mutation and have either come back after treatment or not responded. The goal was to see if the drug could shrink or …
Matched conditions: RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 07:00 UTC
-
New hope for kids with rare cancers: targeted drug selpercatinib tested in phase 2 trial
Disease control OngoingThis phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…
Matched conditions: RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with tough cancers: targeted drug attacks gene flaw
Disease control OngoingThis study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…
Matched conditions: RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Precision drug tipifarnib targets rare HRAS cancers in kids
Disease control OngoingThis study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancers have a specific change in the HRAS gene. The cancers are advanced or have come back after treatment. The goal is to see if tipifarnib can shrink tumors or stop them from growing. A…
Matched conditions: RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can DNA tests pick the right cancer drug for kids?
Knowledge-focused OngoingThis study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…
Matched conditions: RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC